Serious adverse reactions in a tuberculosis programme setting in Kyrgyzstan.

Serious adverse reactions among new smear-positive patients were studied in a programme setting in Kyrgyzstan. Two per cent of patients on tuberculosis (TB) treatment had to interrupt treatment for > or =1 week, and more than 80% of the reactions occurred during the first month of treatment. Pyrazinamide was the most common causative agent, followed by rifampicin.